These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 27228432

  • 1. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial.
    Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, Lederballe O, Rickers H, Kampmann U, Poulsen PL, Hansen KW, Btker HE, Peters CD, Engholm M, Bertelsen JB, Lassen JF, Langfeldt S, Andersen G, Pedersen EB, Kaltoft A.
    J Hypertens; 2016 Aug; 34(8):1639-47. PubMed ID: 27228432
    [Abstract] [Full Text] [Related]

  • 2. The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence.
    Ott C, Mahfoud F, Schmid A, Ewen S, Toennes SW, Meyer MR, Helfer AG, Maurer HH, Ditting T, Veelken R, Zivanovic I, Uder M, Böhm M, Schmieder RE.
    J Hypertens; 2016 Dec; 34(12):2475-2479. PubMed ID: 27607458
    [Abstract] [Full Text] [Related]

  • 3. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial).
    Peters CD, Mathiassen ON, Vase H, Bech Nørgaard J, Christensen KL, Schroeder AP, Rickers HJVH, Opstrup UK, Poulsen PL, Langfeldt S, Andersen G, Hansen KW, Bøtker HE, Engholm M, Bertelsen JB, Pedersen EB, Kaltoft A, Buus NH.
    Blood Press; 2017 Dec; 26(6):366-380. PubMed ID: 28830251
    [Abstract] [Full Text] [Related]

  • 4. Renal denervation in moderate treatment-resistant hypertension.
    Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE.
    J Am Coll Cardiol; 2013 Nov 12; 62(20):1880-6. PubMed ID: 23850901
    [Abstract] [Full Text] [Related]

  • 5. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A, Armario P, Clarà A, Sans-Atxer L, Vázquez S, Pascual J, De la Sierra A.
    J Hypertens; 2016 Sep 12; 34(9):1863-71. PubMed ID: 27327441
    [Abstract] [Full Text] [Related]

  • 6. Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial.
    Engholm M, Bertelsen JB, Mathiassen ON, Bøtker HE, Vase H, Peters CD, Bech JN, Buus NH, Schroeder AP, Rickers H, Hansen KW, Poulsen PL, Kaltoft A, Christensen KL.
    Int J Cardiol; 2018 Jan 01; 250():29-34. PubMed ID: 29042091
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance.
    Ewen S, Cremers B, Meyer MR, Donazzan L, Kindermann I, Ukena C, Helfer AG, Maurer HH, Laufs U, Grassi G, Böhm M, Mahfoud F.
    J Hypertens; 2015 Dec 01; 33(12):2519-25. PubMed ID: 26485463
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators.
    Lancet; 2022 Oct 22; 400(10361):1405-1416. PubMed ID: 36130612
    [Abstract] [Full Text] [Related]

  • 15. Renal denervation for mild-moderate treatment-resistant hypertension : A timely intervention?
    Chen S, Kiuchi MG, Schmidt B, Hoye NA, Acou WJ, Liu S, Chun KRJ, Pürerfellner H.
    Herz; 2019 Aug 22; 44(5):412-418. PubMed ID: 29255910
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial.
    Wang J, Yin Y, Lu C, Lu Z, Hu J, Wang Y, Ge J, Jiang H, Yao C, Yan X, Ma W, Qi X, Dang Y, Chen S, Zhu J, Wang D, Ding C, Wang W, Liu J, Wang Y, Li H, Pan Z, Cui K, Li C, Liang X, Chen W, Sobotka PA, Zhang J, Esler M, Sun N, Chen M, Huo Y.
    EClinicalMedicine; 2024 Jun 22; 72():102626. PubMed ID: 38756107
    [Abstract] [Full Text] [Related]

  • 20. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.
    Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, Schmieder RE, Janas AJ, Langer C, Persu A, Mendelsohn FO, Ameloot K, Foster M, Fischell TA, Parise H, Mahfoud F.
    Circulation; 2024 Jun 11; 149(24):1875-1884. PubMed ID: 38587557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.